[{"id":"ea16c3dc-6884-43c3-8786-5858a4804bcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04024462","created_at":"2021-01-18T19:45:27.762Z","updated_at":"2024-07-02T16:34:26.917Z","phase":"Phase 3","brief_title":"A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer","source_id_and_acronym":"NCT04024462","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PIK3CA","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • PIK3CA mutation • EGFR positive","tags":["PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • PIK3CA mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/05/2020","start_date":" 02/05/2020","primary_txt":" Primary completion: 12/13/2021","primary_completion_date":" 12/13/2021","study_txt":" Completion: 11/11/2025","study_completion_date":" 11/11/2025","last_update_posted":"2024-06-12"},{"id":"0e159834-d55b-493f-b633-ada407fa2107","acronym":"KEYNOTE-603","url":"https://clinicaltrials.gov/study/NCT03313778","created_at":"2021-01-18T16:21:59.009Z","updated_at":"2024-07-02T16:34:59.235Z","phase":"Phase 1","brief_title":"Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors","source_id_and_acronym":"NCT03313778 - KEYNOTE-603","lead_sponsor":"ModernaTX, Inc.","biomarkers":" EGFR • ALK • TMB","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK translocation • EGFR positive","tags":["EGFR • ALK • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK translocation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • mRNA-4157 • pembrolizumab subcutaneous (MK-3475 SC)"],"overall_status":"Recruiting","enrollment":" Enrollment 242","initiation":"Initiation: 08/14/2017","start_date":" 08/14/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-04"},{"id":"9d6eb8a2-227e-4af0-a797-a3385d961585","acronym":"","url":"https://clinicaltrials.gov/study/NCT03742245","created_at":"2021-01-18T18:19:48.582Z","updated_at":"2024-07-02T16:34:59.398Z","phase":"Phase 1","brief_title":"Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer","source_id_and_acronym":"NCT03742245","lead_sponsor":"The Methodist Hospital Research Institute","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Zolinza (vorinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 06/11/2019","start_date":" 06/11/2019","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-06-03"},{"id":"c86caf36-50f7-4e83-bb56-4d558b8c9be3","acronym":"EMBER","url":"https://clinicaltrials.gov/study/NCT04188548","created_at":"2021-01-18T20:25:02.359Z","updated_at":"2024-07-02T16:34:59.967Z","phase":"Phase 1","brief_title":"A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer","source_id_and_acronym":"NCT04188548 - EMBER","lead_sponsor":"Eli Lilly and Company","biomarkers":" ER","pipe":" | ","alterations":" HER-2 negative • EGFR positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • everolimus • Perjeta (pertuzumab) • Piqray (alpelisib) • Verzenio (abemaciclib) • exemestane • imlunestrant (LY3484356)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 12/10/2019","start_date":" 12/10/2019","primary_txt":" Primary completion: 06/29/2020","primary_completion_date":" 06/29/2020","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-05-30"},{"id":"d384c3ae-8417-44ba-b4e7-9e1ff188e51d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05954871","created_at":"2023-07-20T23:11:00.288Z","updated_at":"2024-07-02T16:35:00.306Z","phase":"Phase 1","brief_title":"Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05954871","lead_sponsor":"Genentech, Inc.","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR positive","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Tagrisso (osimertinib) • migoprotafib (RLY-1971)"],"overall_status":"Recruiting","enrollment":" Enrollment 172","initiation":"Initiation: 01/08/2024","start_date":" 01/08/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-29"},{"id":"432f1e5f-02a6-4552-b299-64f4b470c25a","acronym":"heredERA","url":"https://clinicaltrials.gov/study/NCT05296798","created_at":"2022-04-20T16:53:29.043Z","updated_at":"2024-07-02T16:35:00.630Z","phase":"Phase 3","brief_title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","source_id_and_acronym":"NCT05296798 - heredERA","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • EGFR positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • tamoxifen • Perjeta (pertuzumab) • giredestrant (GDC-9545) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 812","initiation":"Initiation: 07/04/2022","start_date":" 07/04/2022","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 09/30/2032","study_completion_date":" 09/30/2032","last_update_posted":"2024-05-28"},{"id":"aef3f3cb-aa50-40d2-b1b1-727aae5c68fd","acronym":"CHRYSALIS","url":"https://clinicaltrials.gov/study/NCT02609776","created_at":"2021-01-17T17:17:24.122Z","updated_at":"2024-07-02T16:35:02.101Z","phase":"Phase 1","brief_title":"Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02609776 - CHRYSALIS","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" ALK • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • EGFR C797S • MET mutation • MET expression • EGFR exon 20 mutation • EGFR positive","tags":["ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • EGFR C797S • MET mutation • MET expression • EGFR exon 20 mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 751","initiation":"Initiation: 05/24/2016","start_date":" 05/24/2016","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-22"},{"id":"beddf205-03cd-41ab-a70e-4c8d6bbed76f","acronym":"Astefania","url":"https://clinicaltrials.gov/study/NCT04873362","created_at":"2021-05-05T11:52:37.025Z","updated_at":"2024-07-02T16:35:03.632Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","source_id_and_acronym":"NCT04873362 - Astefania","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" EGFR positive","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Recruiting","enrollment":" Enrollment 1700","initiation":"Initiation: 05/04/2021","start_date":" 05/04/2021","primary_txt":" Primary completion: 06/25/2026","primary_completion_date":" 06/25/2026","study_txt":" Completion: 06/29/2035","study_completion_date":" 06/29/2035","last_update_posted":"2024-05-15"},{"id":"3c7531a5-d2c1-4a20-9990-f4c698763dbe","acronym":"SPARTA","url":"https://clinicaltrials.gov/study/NCT03175224","created_at":"2022-05-11T08:56:01.997Z","updated_at":"2024-07-02T16:35:04.401Z","phase":"Phase 2","brief_title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","source_id_and_acronym":"NCT03175224 - SPARTA","lead_sponsor":"Apollomics Inc.","biomarkers":" HGF • PTPRZ1","pipe":" | ","alterations":" EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion","tags":["HGF • PTPRZ1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bozitinib (APL-101) • CBT101"],"overall_status":"Recruiting","enrollment":" Enrollment 497","initiation":"Initiation: 09/27/2017","start_date":" 09/27/2017","primary_txt":" Primary completion: 03/30/2026","primary_completion_date":" 03/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-05-10"},{"id":"c19fcf46-da64-4990-816c-fae48ca60bcc","acronym":"ASCENT-J02","url":"https://clinicaltrials.gov/study/NCT05101096","created_at":"2023-08-22T17:08:39.827Z","updated_at":"2024-07-02T16:35:04.448Z","phase":"Phase 1/2","brief_title":"Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05101096 - ASCENT-J02","lead_sponsor":"Gilead Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 143","initiation":"Initiation: 10/20/2021","start_date":" 10/20/2021","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-05-10"},{"id":"b33b770e-2030-41f5-b3a0-0baa9951a5d5","acronym":"ProHer","url":"https://clinicaltrials.gov/study/NCT05415215","created_at":"2022-06-13T16:55:43.094Z","updated_at":"2024-07-02T16:35:09.355Z","phase":"Phase 3","brief_title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","source_id_and_acronym":"NCT05415215 - ProHer","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification • EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • cyclophosphamide • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 347","initiation":"Initiation: 07/05/2022","start_date":" 07/05/2022","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-04-16"},{"id":"5f952e53-c94e-4072-b418-d6bed213f5a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02273362","created_at":"2021-01-18T10:41:42.315Z","updated_at":"2024-07-02T16:35:12.899Z","phase":"Phase 1/2","brief_title":"Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver","source_id_and_acronym":"NCT02273362","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • EGF • PCNA","pipe":" | ","alterations":" EGFR positive","tags":["EGFR • EGF • PCNA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 11/24/2014","start_date":" 11/24/2014","primary_txt":" Primary completion: 02/11/2020","primary_completion_date":" 02/11/2020","study_txt":" Completion: 03/10/2022","study_completion_date":" 03/10/2022","last_update_posted":"2024-03-26"},{"id":"a896ec8e-9825-4531-a478-c93b653bba25","acronym":"","url":"https://clinicaltrials.gov/study/NCT02057133","created_at":"2021-01-17T17:28:58.622Z","updated_at":"2024-07-02T16:35:13.024Z","phase":"Phase 1","brief_title":"A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread","source_id_and_acronym":"NCT02057133","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • CDK4 • CDK6","pipe":" | ","alterations":" HR positive • HER-2 negative • EGFR positive","tags":["HER-2 • CDK4 • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • everolimus • tamoxifen • Perjeta (pertuzumab) • Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • exemestane • samotolisib (LY3023414) • loperamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 03/10/2014","start_date":" 03/10/2014","primary_txt":" Primary completion: 03/15/2021","primary_completion_date":" 03/15/2021","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-25"},{"id":"0b6e5ad5-c4b9-4e11-ac82-4f01f7ab9b5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04834778","created_at":"2021-04-08T13:52:24.698Z","updated_at":"2024-07-02T16:35:15.757Z","phase":"Phase 1","brief_title":"A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)","source_id_and_acronym":"NCT04834778","lead_sponsor":"HiberCell, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HC-5404"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 06/08/2021","start_date":" 06/08/2021","primary_txt":" Primary completion: 12/07/2023","primary_completion_date":" 12/07/2023","study_txt":" Completion: 01/30/2024","study_completion_date":" 01/30/2024","last_update_posted":"2024-03-08"},{"id":"41be4368-ac8d-41a5-97f4-07c00abcbd42","acronym":"ADAPT-E","url":"https://clinicaltrials.gov/study/NCT04585477","created_at":"2023-03-02T18:01:37.004Z","updated_at":"2024-07-02T16:35:17.732Z","phase":"Phase 2","brief_title":"Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)","source_id_and_acronym":"NCT04585477 - ADAPT-E","lead_sponsor":"Stanford University","biomarkers":" PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • PD-L1 overexpression • EGFR L858R • EGFR exon 19 deletion • EGFR expression • ALK rearrangement • ROS1 rearrangement • EGFR positive","tags":["PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • PD-L1 overexpression • EGFR L858R • EGFR exon 19 deletion • EGFR expression • ALK rearrangement • ROS1 rearrangement • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/08/2021","start_date":" 04/08/2021","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-02-26"},{"id":"1d2920ad-7680-4e69-b51f-ddb29e043f61","acronym":"ACT","url":"https://clinicaltrials.gov/study/NCT05238831","created_at":"2023-08-08T16:08:43.868Z","updated_at":"2024-07-02T16:35:22.520Z","phase":"Phase 1","brief_title":"SMMART Adaptive Clinical Treatment (ACT) Trial","source_id_and_acronym":"NCT05238831 - ACT","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" HER-2 • BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • EGFR positive","tags":["HER-2 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • carboplatin • Rozlytrek (entrectinib) • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • capecitabine • Piqray (alpelisib) • Zejula (niraparib) • albumin-bound paclitaxel • fulvestrant • irinotecan • Halaven (eribulin mesylate) • letrozole • vinorelbine tartrate • Herzuma (trastuzumab-pkrb) • anastrozole • Erivedge (vismodegib) • Trazimera (trastuzumab-qyyp) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • EG1206A (pertuzumab biosimilar)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/30/2023","start_date":" 01/30/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-01-23"},{"id":"85201425-83fc-431f-9c04-0410092876c4","acronym":"TBCRC 050","url":"https://clinicaltrials.gov/study/NCT03368729","created_at":"2021-01-18T16:37:35.798Z","updated_at":"2024-07-02T16:35:24.843Z","phase":"Phase 1/2","brief_title":"Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer","source_id_and_acronym":"NCT03368729 - TBCRC 050","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" PGR","pipe":" | ","alterations":" ER positive + PGR positive • PGR positive • EGFR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive + PGR positive • PGR positive • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Zejula (niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/06/2019","start_date":" 09/06/2019","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-01-01"},{"id":"7d41bb5c-8775-4bbb-9bda-315d6ca7d0d0","acronym":"SELECT-2","url":"https://clinicaltrials.gov/study/NCT04401059","created_at":"2023-12-27T18:16:50.631Z","updated_at":"2024-07-02T16:35:25.073Z","phase":"Phase 4","brief_title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study","source_id_and_acronym":"NCT04401059 - SELECT-2","lead_sponsor":"Tian Xie","biomarkers":" EGFR • ALK • TP53 • MSI • PTEN • STK11 • JAK2 • PBRM1 • JAK1 • MDM4 • POLD1","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR positive","tags":["EGFR • ALK • TP53 • MSI • PTEN • STK11 • JAK2 • PBRM1 • JAK1 • MDM4 • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • erlotinib • gefitinib • Conmana (icotinib) • Ameile (aumolertinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 744","initiation":"Initiation: 11/09/2020","start_date":" 11/09/2020","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 03/30/2026","study_completion_date":" 03/30/2026","last_update_posted":"2023-12-27"},{"id":"12c5598d-a506-4d5a-ac24-402030731a86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04906369","created_at":"2021-05-28T13:52:36.210Z","updated_at":"2024-07-02T16:35:25.207Z","phase":"","brief_title":"Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring","source_id_and_acronym":"NCT04906369","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • EGFR positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • EGFR positive"],"overall_status":"Suspended","enrollment":" Enrollment 150","initiation":"Initiation: 11/16/2020","start_date":" 11/16/2020","primary_txt":" Primary completion: 11/15/2024","primary_completion_date":" 11/15/2024","study_txt":" Completion: 11/15/2024","study_completion_date":" 11/15/2024","last_update_posted":"2023-12-25"},{"id":"961758d0-6679-4971-b806-6a0fe59d5b35","acronym":"ROSE","url":"https://clinicaltrials.gov/study/NCT05089916","created_at":"2021-10-22T12:53:07.379Z","updated_at":"2024-07-02T16:35:25.236Z","phase":"Phase 2","brief_title":"Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study","source_id_and_acronym":"NCT05089916 - ROSE","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/20/2022","start_date":" 01/20/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-12-25"},{"id":"b87343c1-60c6-4d17-aa70-17fd08c5a752","acronym":"PORT-N1","url":"https://clinicaltrials.gov/study/NCT05440149","created_at":"2022-06-30T15:54:17.265Z","updated_at":"2024-07-02T16:35:28.155Z","phase":"Phase 3","brief_title":"The Postoperative Radiotherapy in N1 Breast Cancer Patients","source_id_and_acronym":"NCT05440149 - PORT-N1","lead_sponsor":"Seoul National University Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • EGFR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 1106","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2033","study_completion_date":" 12/31/2033","last_update_posted":"2023-11-24"},{"id":"956a13f3-aa9f-4359-9b4f-4739b5b057ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT05293470","created_at":"2022-03-24T14:52:55.695Z","updated_at":"2024-07-02T16:35:28.510Z","phase":"","brief_title":"A Post Marketing Surveillance on Piqray in Korea","source_id_and_acronym":"NCT05293470","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • PIK3CA","pipe":" | ","alterations":" EGFR mutation • HR positive • HER-2 negative • PIK3CA mutation • EGFR positive","tags":["HER-2 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HR positive • HER-2 negative • PIK3CA mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib)"],"overall_status":"Recruiting","enrollment":" Enrollment 900","initiation":"Initiation: 06/29/2022","start_date":" 06/29/2022","primary_txt":" Primary completion: 05/12/2027","primary_completion_date":" 05/12/2027","study_txt":" Completion: 05/12/2027","study_completion_date":" 05/12/2027","last_update_posted":"2023-11-21"},{"id":"7e9c533e-cc6e-4694-9c54-aa34b9f00feb","acronym":"TROPiCS-02","url":"https://clinicaltrials.gov/study/NCT03901339","created_at":"2021-01-17T17:20:16.035Z","updated_at":"2024-07-02T16:35:28.572Z","phase":"Phase 3","brief_title":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer","source_id_and_acronym":"NCT03901339 - TROPiCS-02","lead_sponsor":"Gilead Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Completed","enrollment":" Enrollment 543","initiation":"Initiation: 05/08/2019","start_date":" 05/08/2019","primary_txt":" Primary completion: 10/20/2023","primary_completion_date":" 10/20/2023","study_txt":" Completion: 10/20/2023","study_completion_date":" 10/20/2023","last_update_posted":"2023-11-20"},{"id":"657a150b-5f41-44b4-ab84-352d511b0114","acronym":"","url":"https://clinicaltrials.gov/study/NCT01325441","created_at":"2021-01-18T05:23:55.341Z","updated_at":"2024-07-02T16:35:29.056Z","phase":"Phase 1/2","brief_title":"A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies","source_id_and_acronym":"NCT01325441","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" BRAF • ER • ALK • PGR","pipe":" | ","alterations":" HER-2 positive • BRAF V600E • HER-2 negative • BRAF V600 • ALK positive • BRAF V600K • BRAF wild-type • ER negative • EGFR positive • PGR negative","tags":["BRAF • ER • ALK • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRAF V600E • HER-2 negative • BRAF V600 • ALK positive • BRAF V600K • BRAF wild-type • ER negative • EGFR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • albumin-bound paclitaxel • napabucasin (BBI608)"],"overall_status":"Completed","enrollment":" Enrollment 565","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2023-11-15"}]